利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.017 秒)

    DNA METHYLATION MARKERS FOR METASTATIC PROSTATE CANCER
    1.
    发明申请
    DNA METHYLATION MARKERS FOR METASTATIC PROSTATE CANCER 审中-公开
    用于分子前列腺癌的DNA甲基标记物

    公开(公告)号：US20140274767A1

    公开(公告)日：2014-09-18

    申请号：US14162180

    申请日：2014-01-23

    申请人： THE JOHNS HOPKINS UNIVERSITY

    发明人： Srinivasan Yegnasubramanian ,  G. Steven Bova ,  Martin Aryee ,  William B. Isaacs ,  William G. Nelson

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q1/6855 ,  C12Q2600/154 ,  C12Q2537/164 ,  C12Q2565/501 ,  C12Q2565/531

    摘要： The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.

    摘要翻译： 本发明涉及癌症领域。 更具体地，本发明提供了可用于评估前列腺癌的方法和组合物。 在一个具体的实施方案中，本发明人已经开发并应用了一种能够同时进行基因组（拷贝数）和表观遗传学（总甲基化（TM））和等位基因特异性甲基化（ASM）交替的基因组大规模分析的新技术和相关计算方法。 称为MBD-SNP，使用甲基结合结构域多肽具有亲和力富集或甲基化基因组DNA片段。

    Induction of synthetic lethality with epigenetic therapy
    2.
    发明授权
    Induction of synthetic lethality with epigenetic therapy 有权

    公开(公告)号：US11491174B2

    公开(公告)日：2022-11-08

    申请号：US16618845

    申请日：2018-06-06

    申请人： The Johns Hopkins University

    发明人： Srinivasan Yegnasubramanian ,  William G. Nelson ,  Ajay Vaghasia ,  Philipp Nuhn

    IPC分类号： A61K31/7068 ,  A61P35/00 ,  A61K31/203 ,  A61K31/4188 ,  A61K31/55

    摘要： The disclosure generally relates to compositions and methods for the treatment of cancer. In some aspects, disclosed herein are methods for the induction of synthetic lethality with epigenetic therapy (ISLET) using a combination of at least one epigenetic compound and at least one chemotherapeutic agent. Also disclosed herein are screening methods for identifying compounds that induce killing of cancer cells when combined with at least one epigenetic compound. Further disclosed herein are methods of potentiating a therapeutic effect of a chemotherapeutic agent against a cancer, comprising administering to a subject having the cancer an epigenetic compound in an amount effective to potentiate the therapeutic effect of the chemotherapeutic agent against the cancer.

    5-hydroxymethylcytosine in human cancer
    4.
    发明授权
    5-hydroxymethylcytosine in human cancer 有权
    人类癌症中的5-羟甲基胞嘧啶

    公开(公告)号：US09297806B2

    公开(公告)日：2016-03-29

    申请号：US13956879

    申请日：2013-08-01

    申请人： The Johns Hopkins University

    发明人： Srinivasan Yegnasubramanian ,  Michael Christoph Haffner ,  Alcides Chaux ,  William G. Nelson ,  Angelo M. DeMarzo

    IPC分类号： G01N33/53 ,  G01N33/574

    CPC分类号： G01N33/57496 ,  G01N2800/50

    摘要： The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for diagnosing or predicting cancer in a patient. In one embodiment, a method for identifying a patient as having cancer comprises the steps of (a) providing a formalin-fixed, paraffin-embedded or fresh frozen sample of patient tissue; (b) steaming the sample in antigen retrieval buffer; (c) incubating the sample in hydrochloric acid (HCl); (d) incubating the sample with an affinity reagent specific for 5hmC under conditions to form a complex between the affinity reagent and 5-hydroxymethylcytosine (5hmC) present in the sample; (e) detecting the complexes formed between 5hmC and the affinity reagent with secondary detection reagents; (f) quantifying 5hmC levels; and (g) identifying the patient as having cancer if the 5hmC levels in the sample are reduced as compared to a control.

    摘要翻译： 本发明涉及癌症领域。 更具体地，本发明提供了可用于诊断或预测患者中的癌症的方法和组合物。 在一个实施方案中，用于鉴定患者具有癌症的方法包括以下步骤：（a）提供患有组织的福尔马林固定，石蜡包埋或新鲜冷冻的样品; （b）在抗原检索缓冲液中蒸煮样品; （c）将样品在盐酸（HCl）中孵育; （d）在条件下用特异于5hmC的亲和试剂培养样品，以形成样品中存在的亲和试剂和5-羟甲基胞嘧啶（5hmC）之间的复合物; （e）用二级检测试剂检测在5hmC与亲和试剂之间形成的复合物; （f）量化5hmC水平; 如果与对照相比，如果样品中的5hmC水平降低，则鉴定患者具有癌症。

    INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY
    9.
    发明申请
    INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY 有权

    公开(公告)号：US20230100402A1

    公开(公告)日：2023-03-30

    申请号：US17946416

    申请日：2022-09-16

    申请人： The Johns Hopkins University

    发明人： Srinivasan Yegnasubramanian ,  William G. Nelson ,  Ajay Vaghasia ,  Philipp Nuhn

    IPC分类号： A61K31/7068 ,  A61P35/00 ,  A61K31/203 ,  A61K31/4188 ,  A61K31/55

    摘要： The disclosure generally relates to compositions and methods for the treatment of cancer. In some aspects, disclosed herein are methods for the induction of synthetic lethality with epigenetic therapy (ISLET) using a combination of at least one epigenetic compound and at least one chemotherapeutic agent. Also disclosed herein are screening methods for identifying compounds that induce killing of cancer cells when combined with at least one epigenetic compound. Further disclosed herein are methods of potentiating a therapeutic effect of a chemotherapeutic agent against a cancer, comprising administering to a subject having the cancer an epigenetic compound in an amount effective to potentiate the therapeutic effect of the chemotherapeutic agent against the cancer.